Commercial consultant for pre-commercial biotech: Go-to-market strategy and launch planning, 5-year operational budget, consult on pivotal trial design, and develop investor pitch deck.

**Leadership** - Led a team of eight seasoned marketers, recruiting and hiring seven while promoting one to a leadership role mid-cycle. - Presented a business case to the CEO, CCO, and Board of Directors, resulting in the restructuring of the brand marketing team and the creation of three new headcounts to execute the strategy effectively. - Founded and led a cross-functional, cross-alliance working group to drive key business priorities, accelerating both near- and long-term growth. - Core member of the R&D Program Team, setting the vision, identifying data gaps, and developing a budget for key studies. These efforts led to NCCN guideline updates, removing the exclusion of Orgovyx in combination therapies. - Co-led the Joint Commercial Committee, an alliance decision-making body responsible for investments in brand tactics, OPEX, and the Brand Plan. - Served as Interim General Manager (GM), aligning Pfizer’s Commercial leadership on key patents and LOE extensions, informing peak year sales projections and unlocking investments into clinical trials targeting MACE events. **Strategy & Execution** - Presented a business case to the CEO and CCO to revamp the brand strategy and refine customer segmentation. - Identified a key HCP segment and equipped the brand team to develop personalized content, shaping the market effectively. **Financial & Operational** - Achieved market leadership within the antagonist class, becoming the #1 prescribed ADT for new patient-starts in Urology clinics. - Managed a $62M annual OPEX, encompassing brand promotions, market access, and patient free-drug programs. - Held P&L responsibility, overseeing headcount, forecasting, and operational budgets across functions. - Led commercial decisions on pricing, contracting, and rebates, maintaining favorable YoY Gross-to-Net (GTN). - Increased annual patients treated from 13K to over 30K, driving significant growth.

***by way of acquisition of Juno Therapeutics 2018 and Celgene 2019***• Led the development and execution of US future indications program for Breyanzi®, including 2L LBCL, Follicular Lymphoma, MZL, MCL, and CLL.• Built core commercial capabilities in the CAR-T space, overseeing brand P&L and manufacturing 3-year slot allocation plan.• Developed partnerships with key stakeholders in leukemia, lymphoma, and cell therapy space to enhance brand positioning.

***acquired by Pfizer 9/2016**

Blinatumomab U.S. Launch Team.Sr. Product Manager – Promotions Marketing & Strategy, Launch Brand Team – BLINCYTO® for the treatment of Refractory/Relapsed Acute Lymphoblastic Leukemia, Philadelphia B negative - an orphan disease classification and Breakthrough Therapy designation by the FDA. Utilizing novel BiTE technology, FDA approved BLA in just 75 days based on Phase II data.Summary - Blinatumomab U.S. launch team. LCM strategy: Developing Pediatric indication strategy, targeting, messages. Mandatory OPDP promotional tools pre-clearance – responsible for Wave 2 OPDP submission.• Marketing – Lead on Core Visual Aid, Blincyto.com, and all Multi-Channel strategy and Journal advertisements including web banners and print journal development and the OPDP submission for Wave 2 pre-clearance.o Market Research – multi-city qualitative research on Wave 2 CVA and messageso Onyx integration Teammate – Blincyto is first molecule to move from Amgen to Onyx. Advisory member on Integration team to ensure knowledge transfer is successful.• Strategy Planning – Lead on Pediatric Indication strategy,

Evolocumab (AMG-145) U.S. launch team. • Market Development – U.S. strategy and Disease Education targeting U.S. HCPs on a new class of mAbs that targets the PCSK9.

Enbrel promotions marketing

Nephrology Portfolio - Key Accounts including Large & Small Dialysis Organizations, System Hospitals, Injection Clinics and Nephrology medical clinics.

Fosamax, Singulair